Two different classes of therapy-related and de-novo acute myeloid leukemia?

Cancer Genet Cytogenet. 1991 Aug;55(1):119-24. doi: 10.1016/0165-4608(91)90246-q.


Two different classes of therapy-related acute myeloid leukemia (t-AML) seem to emerge. One class follows therapy with alkylating agents, increases in frequency with age, often presents with myelodysplasia (MDS), responds poorly to chemotherapy, and shows monosomy 7(-7), monosomy 5(-5), or loss of various parts of the long arms of these chromosomes (5q- and 7q-). The other class is related to therapy with cytostatic drugs targeting at DNA-topoisomerase II, often presents with overt leukemia, responds more favorably to chemotherapy, and shows balanced chromosome aberrations, primarily translocations involving chromosome bands 11q23 and 21q22. These two classes of t-AML may have their counterparts in de-novo acute myeloid leukemia (de-novo AML).

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Chromosome Aberrations*
  • Chromosome Banding
  • Humans
  • Leukemia, Myeloid / chemically induced
  • Leukemia, Myeloid / classification
  • Leukemia, Myeloid / genetics*
  • Monosomy
  • Myelodysplastic Syndromes / chemically induced
  • Myelodysplastic Syndromes / classification
  • Myelodysplastic Syndromes / genetics*
  • Neoplasms, Second Primary*
  • Topoisomerase II Inhibitors
  • Translocation, Genetic


  • Antineoplastic Agents
  • Topoisomerase II Inhibitors